Other disclosuresNSE · BLISSGVS
Bliss GVS Pharma Limited
Updates
01 / The disclosure
What the company shared
Bliss GVS Pharma Limited has informed the Exchange regarding 'Intimation under Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Grant of Marketing Authorisation from MHRA, UK for Mesalazine 1g Suppositories'.
Exchange-provided summary Company profile
A question for your research
Read the underlying filing for the complete disclosure and any conditions not included in the exchange summary.
The evidence
Read the source excerpts
PDF text is unavailable. Read the original filing for the full disclosure.
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- 106844769
- First collected
- 4 Nov 2026, 17:21 IST
- PDF extraction
- metadata_only
You’ve reached the end of this disclosure.